

Claudio Marocco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/750597/publications.pdf>

Version: 2024-02-01

103
papers

8,124
citations

94433

37
h-index

51608

86
g-index

109
all docs

109
docs citations

109
times ranked

6057
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3561-3569.	3.6	1,277
2	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. <i>European Thyroid Journal</i> , 2016, 5, 9-26.	2.4	738
3	Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. <i>Endocrine Reviews</i> , 2019, 40, 1109-1151.	20.1	611
4	Selenium and the Course of Mild Graves' Orbitopathy. <i>New England Journal of Medicine</i> , 2011, 364, 1920-1931.	27.0	503
5	Teprotumumab for the Treatment of Active Thyroid Eye Disease. <i>New England Journal of Medicine</i> , 2020, 382, 341-352.	27.0	375
6	The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. <i>European Journal of Endocrinology</i> , 2021, 185, G43-G67.	3.7	362
7	Primary Hyperparathyroidism. <i>New England Journal of Medicine</i> , 2011, 365, 2389-2397.	27.0	312
8	Parathyroid Carcinoma. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1869-1880.	2.8	243
9	Genetic Analyses of the <i>HRPT2</i> Gene in Primary Hyperparathyroidism: Germline and Somatic Mutations in Familial and Sporadic Parathyroid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5583-5591.	3.6	234
10	Diagnosis and classification of Graves' disease. <i>Autoimmunity Reviews</i> , 2014, 13, 398-402.	5.8	205
11	Primary hyperparathyroidism. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16033.	30.5	180
12	Medical Management of Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3607-3618.	3.6	179
13	Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2766-2772.	3.6	134
14	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 287-298.	11.4	128
15	Controversies in Vitamin D: A Statement From the Third International Conference. <i>JBMR Plus</i> , 2020, 4, e10417.	2.7	118
16	Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. <i>European Journal of Endocrinology</i> , 2012, 166, 247-253.	3.7	112
17	Long-Term Safety of Orbital Radiotherapy for Graves' Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3561-3566.	3.6	105
18	PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. <i>British Journal of Ophthalmology</i> , 2015, 99, 1531-1535.	3.9	92

#	ARTICLE	IF	CITATIONS
19	Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, R441-R464.	3.1	87
20	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. <i>Endocrine</i> , 2017, 58, 349-359.	2.3	77
21	CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. <i>Endocrine Connections</i> , 2013, 2, 186-195.	1.9	76
22	Oxidative Stress in Graves' Disease. <i>European Thyroid Journal</i> , 2012, 1, 80-87.	2.4	74
23	Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1201-1218.	5.7	74
24	European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). <i>European Journal of Endocrinology</i> , 2022, 186, R33-R63.	3.7	73
25	Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 325-337.	4.7	66
26	High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study. <i>Thyroid</i> , 2018, 28, 386-394.	4.5	64
27	Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT). <i>European Journal of Endocrinology</i> , 2019, 181, P1-P19.	3.7	61
28	Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy. <i>Thyroid</i> , 2017, 27, 271-278.	4.5	53
29	Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy. <i>JAMA Ophthalmology</i> , 2018, 136, 613.	2.5	52
30	Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome. <i>Journal of the Endocrine Society</i> , 2019, 3, 496-503.	0.2	50
31	Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. <i>European Thyroid Journal</i> , 2019, 8, 192-195.	2.4	49
32	Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study. <i>European Journal of Endocrinology</i> , 2015, 172, 269-276.	3.7	48
33	Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4. <i>Endocrine Connections</i> , 2015, 4, 1-8.	1.9	44
34	Bone disease in primary hyperparathyroidism. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 357-368.	2.7	43
35	Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. <i>Endocrine</i> , 2017, 55, 256-265.	2.3	42
36	Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. <i>Endocrine</i> , 2017, 55, 386-397.	2.3	42

#	ARTICLE	IF	CITATIONS
37	A 2016 Italian Survey about the Clinical Use of Selenium in Thyroid Disease. <i>European Thyroid Journal</i> , 2016, 5, 164-170.	2.4	41
38	Role of the Underlying Thyroid Disease on the Phenotype of Graves' Orbitopathy in a Tertiary Referral Center. <i>Thyroid</i> , 2015, 25, 347-351.	4.5	38
39	Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 242-251.	3.6	36
40	Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2019, 2019, .	0.5	35
41	Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism. <i>Clinical Endocrinology</i> , 2002, 56, 457-464.	2.4	32
42	Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy. <i>Thyroid</i> , 2015, 25, 846-850.	4.5	32
43	Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. <i>PLoS ONE</i> , 2017, 12, e0186485.	2.5	31
44	Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2016, 175, 443-453.	3.7	29
45	Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1581-1588.	3.6	27
46	Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 733-742.	11.4	27
47	Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. <i>European Journal of Endocrinology</i> , 2017, 177, 127-135.	3.7	26
48	Selenium in the Treatment of Graves'™ Hyperthyroidism and Eye Disease. <i>Frontiers in Endocrinology</i> , 2020, 11, 608428.	3.5	24
49	Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients'™ survival. <i>Endocrine</i> , 2017, 58, 574-581.	2.3	23
50	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	3.1	23
51	PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e372-e385.	3.6	23
52	Oxidative Stress in Graves Disease and Graves Orbitopathy. <i>European Thyroid Journal</i> , 2020, 9, 40-50.	2.4	22
53	Novel aspects of immunosuppressive and radiotherapy management of Graves'™ ophthalmopathy. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 272-280.	3.3	21
54	Enalapril Reduces Proliferation and Hyaluronic Acid Release in Orbital Fibroblasts. <i>Thyroid</i> , 2013, 23, 92-96.	4.5	21

#	ARTICLE	IF	CITATIONS
55	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , 2018, 62, 215-233.	2.3	21
56	A treatment strategy for Graves' orbitopathy. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 430-436.	2.8	20
57	TSH suppressive therapy and bone. <i>Endocrine Connections</i> , 2020, 9, R158-R172.	1.9	20
58	Non-surgical management of primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 821-835.	4.7	19
59	A nonfunctioning parathyroid carcinoma misdiagnosed as a follicular thyroid nodule. <i>World Journal of Surgical Oncology</i> , 2015, 13, 270.	1.9	18
60	Epidemiology, pathogenesis of primary hyperparathyroidism: Current data. <i>Annales D'Endocrinologie</i> , 2015, 76, 113-115.	1.4	18
61	Genetic Profiling of Orbital Fibroblasts from Patients with Graves'™ Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2176-e2190.	3.6	18
62	Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland. <i>PLoS ONE</i> , 2016, 11, e0146729.	2.5	18
63	Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves'™ orbitopathy. <i>Endocrine</i> , 2017, 58, 386-389.	2.3	17
64	Hereditary Hypercalcemia Caused by a Homozygous Pathogenic Variant in the <i>CYP24A1</i> Gene: A Case Report and Review of the Literature. <i>Case Reports in Endocrinology</i> , 2019, 2019, 1-7.	0.4	17
65	Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review. <i>European Journal of Endocrinology</i> , 2022, 186, 137-149.	3.7	17
66	Does Graves'™ Orbitopathy Ever Disappear Answers to an Old Question. <i>European Thyroid Journal</i> , 2017, 6, 263-270.	2.4	16
67	Mechanistic Pathways of Selenium in the Treatment of Graves'™ Disease and Graves'™ Orbitopathy. <i>Hormone and Metabolic Research</i> , 2018, 50, 887-893.	1.5	16
68	Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2021, 28, 111-134.	3.1	14
69	Treatment options for Graves' orbitopathy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 795-806.	1.8	13
70	Current Medical Management of Graves Ophthalmopathy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2002, 18, 402-408.	0.8	12
71	Circulating Long Non-Coding RNA GAS5 Is Overexpressed in Serum from Osteoporotic Patients and Is Associated with Increased Risk of Bone Fragility. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6930.	4.1	12
72	Hypomagnesuria is Associated With Nephrolithiasis in Patients With Asymptomatic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2789-e2795.	3.6	12

#	ARTICLE	IF	CITATIONS
73	Natural history of gravesâ€™ orbitopathy after treatment. <i>Endocrine</i> , 2017, 57, 226-233.	2.3	11
74	Do the Heterozygous Carriers of a <i>CYP24A1</i> Mutation Display a Different Biochemical Phenotype Than Wild Types?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 708-717.	3.6	11
75	Long-term Efficacy and Safety of Rifampin in the Treatment of a Patient Carrying a <i>CYP24A1</i> Loss-of-Function Variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3159-e3166.	3.6	11
76	Circulating MicroRNAs as Biomarkers of Osteoporosis and Fragility Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2267-2285.	3.6	10
77	Selenium in the Treatment of Thyroid Diseases. <i>European Thyroid Journal</i> , 2017, 6, 113-114.	2.4	9
78	A rapid screening of a recurrent <i>CYP24A1</i> pathogenic variant opens the way to molecular testing for Idiopathic Infantile Hypercalcemia (IIH). <i>Clinica Chimica Acta</i> , 2018, 482, 8-13.	1.1	9
79	Parathyroid Carcinoma and Adenoma Co-existing in One Patient: Case Report and Comparative Proteomic Analysis. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 781-796.	2.0	9
80	Antioxidant Therapy in Gravesâ€™ Orbitopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 608733.	3.5	8
81	PCB153 reduces apoptosis in primary cultures of murine pituitary cells through the activation of NF- κ B mediated by PI3K/Akt. <i>Molecular and Cellular Endocrinology</i> , 2021, 520, 111090.	3.2	8
82	Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1375-1390.	2.6	8
83	Development of an algorithm to predict serum vitamin D levels using a simple questionnaire based on sunlight exposure. <i>Endocrine</i> , 2017, 55, 85-92.	2.3	7
84	Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis. <i>European Thyroid Journal</i> , 2021, 10, 237-247.	2.4	7
85	Do Patients With Atypical Parathyroid Adenoma Need Close Follow-up?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4565-e4579.	3.6	7
86	Clinical profile of juvenile primary hyperparathyroidism: a prospective study. <i>Endocrine</i> , 2018, 59, 344-352.	2.3	6
87	Pseudohypoparathyroidism: Focus on Cerebral and Renal Calcifications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3005-e3020.	3.6	6
88	Effect of neridronate in osteopenic patients after heart, liver or lung transplant: a multicenter, randomized, double-blind, placebo-controlled study. <i>Panminerva Medica</i> , 2021, 63, 214-223.	0.8	5
89	Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 421.	2.7	5
90	Parathyroid Carcinoma and Ectopic Secretion of Parathyroid hormone. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 683-709.	3.2	5

#	ARTICLE	IF	CITATIONS
91	<i>HRPT2</i> gene analysis and the diagnosis of parathyroid carcinoma. Expert Review of Endocrinology and Metabolism, 2008, 3, 377-389.	2.4	4
92	Twentieth EUGOGO Anniversary Symposium. European Thyroid Journal, 2020, 9, 1-2.	2.4	4
93	Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?. Acta Haematologica, 2021, 144, 302-307.	1.4	4
94	Statins: A New Hope on the Horizon of Graves Orbitopathy?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2819-e2821.	3.6	4
95	Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study. Journal of Endocrinological Investigation, 2021, 44, 2575-2579.	3.3	4
96	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. Journal of the Endocrine Society, 2021, 5, bvab093.	0.2	3
97	Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye. European Thyroid Journal, 2018, 7, 51-54.	2.4	2
98	A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature. Endocrine, 2020, 67, 466-472.	2.3	2
99	Dietary calcium intake in a cohort of individuals evaluated for low bone mineral density: a multicenter Italian study. Aging Clinical and Experimental Research, 2021, , 1.	2.9	2
100	A Case of Unilateral Dermopathy Possibly Related to Graves' Disease. European Thyroid Journal, 2019, 8, 278-282.	2.4	1
101	A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. Molecular and Clinical Oncology, 2018, 8, 449-452.	1.0	0
102	Late-onset postsurgical hypoparathyroidism following parathyroidectomy for recurrent primary hyperparathyroidism: a case report and literature review. Endocrine, 2020, 69, 402-409.	2.3	0
103	Hypercalcemia. Endocrinology and Metabolism Clinics of North America, 2021, 50, xv-xvi.	3.2	0